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Abstract
Intratumoral hypoxia is a major obstacle in the development of effective cancer chemotherapy, decreasing the efficacy of
anti-neoplastic drugs in several solid tumours. The hypoxic environment, through its master regulator hypoxia inducible
factor-1 (HIF-1), is able to maintain an anti-apoptotic potential through activation of critical genes associated with drug
resistance. Besides affecting metabolism and motility of tumour cells, hypoxia also paradoxically increases production of
reactive oxygen species (ROS), which contribute to stabilize HIF-1 through a redox-mediated inhibition of its proteolysis.
Here we reported that 1% O2 hypoxia increases the resistance of human metastatic melanoma cells to conventional
chemotherapy with etoposide, and that the increase in chemoresistance strongly depends on ROS delivery due to hypoxia.
We reported a biphasic redox-dependent role of HIF-1, involving mitochondrial complex III and NADPH oxidase as oxidants
sources, synergising in enhancing survival to chemotherapy. The feed-forward loop engaged by hypoxia involves first an
HIF-1-dependent vascular endothelial growth factor-A (VEGF-A) autocrine production and, in the later phase, activation of
NADPH oxidase from VEGF/VEGFR2 interaction, finally leading to a further redox-dependent long lasting stabilization of HIF-
1. We therefore identified a redox-dependent circuitry linking hypoxia-driven ROS to VEGF-A secretion and to enhanced
melanoma cell survival to etoposide chemotherapy.
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Introduction
Melanoma is the most aggressive form of skin cancer and its
advanced stages are inevitably associated with a poor prognosis,
due to their resistance to conventional therapeutic agents. In
particular, the resistance to undergo apoptosis in response to
chemotherapy and other environmental cues gives rise in
aggressive melanoma to a selective advantage for tumour
progression, metastasis formation as well as for resistance to
therapy [1,2].
Acquired resistance to chemotherapy is generally considered to
be the result of the gradual selection of mutant subpopulations,
genetic mutations and biochemical alterations. Of note, tumour
microenvironment is known to contribute in different ways to drug
resistance essentially through increasing cancer mutation rate or
creating a selective pressure favouring resistant and aggressive
populations [3]. Two interesting components of the tumour
microenvironment are hypoxia and reactive oxygen species
(ROS), often reported as strong activators of cancer progression
and correlated with poor outcome for patients [4,5].
Hypoxia is frequent in solid tumours, being the natural
consequence of the increased oxygen diffusion distance due to
tumour expansion [6]. The transcriptional response of mamma-
lian cells to hypoxia is largely mediated by hypoxia-inducible
factor-1 (HIF-1) [7–9]. HIF-1 is a basic helix-loop-helix transcrip-
tion factor composed of an HIF-1b subunit, which is constitutively
expressed, and an HIF-a subunit, which is strongly up-regulated
under hypoxic conditions. At least 3 isoforms of the a subunit have
been identified so far, although HIF-1a is the master regulator of
the transcriptional response to hypoxia. In normoxic conditions,
HIF-1a is degraded by a mechanism involving hydroxylation of 2
prolyl residues, ubiquitination and proteasomal degradation
through a VHL-dependent pathway. Stabilization of HIF-1a is
also influenced by genetic alterations, as well as by growth factors,
hormones and cytokines produced by both tumour and stromal
cells [10]. Under hypoxic condition HIF-1 coordinates the
expression of many genes that orchestrate angiogenesis and
cancer cell metabolism reprogramming, including GLUT1 and
GLUT3, glycolytic enzymes, vascular endothelial growth factor
(VEGF), erythropoietin (EPO), heme oxygenase-1 (HO-1), etc
[11].
Under hypoxic conditions, the hydroxylation of HIF-1a is
inhibited, and HIF-1a is stabilized and competent to activate
transcription of target genes. ROS, in turn, inactivate prolyl
hydroxylases (PHDs) through oxidation of the ferrous ion that is
essential for their catalytic mechanism, and hence stabilize HIF-
1a. Vitamin C has been shown to decrease HIF-1 levels by
preventing the oxidation of the catalytic ferrous ion [12–14]. In
keeping, it has been recently reported that the anti-tumorigenic
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effect of antioxidants as N-acetyl cysteine (NAC) and vitamin C in
murine models of Myc-mediated tumorigenesis are indeed HIF-1-
dependent [15].
Hypoxia is closely related to oxidative stress. Of note, the
genetic disruption of the PHD1 gene in hypoxic mice lowers
oxygen consumption in the mitochondria of skeletal muscle,
reduces oxidative stress, and eventually enhances cellular survival
[16]. In keeping, we have recently observed that during hypoxia
melanoma cells are subjected to persistent oxidative stress due to
increase their intracellular concentration of ROS, due to
mitochondrial complex III deregulation [17]. Mitochondrial
ROS have been largely involved in ROS development and
consequent HIF-1 stabilization under hypoxia [18], as well as for
non hypoxic conditions [19]. Beside mitochondria, NADPH
oxidases have been greatly involved in ROS production and in
redox-dependent HIF-1 stabilization, although mainly in nor-
moxic conditions. Indeed, NADPH-driven ROS have been
involved in HIF-1 activation upon Src activation, after hyperther-
mia treatments, or in macrophages activated by lipopolysaccha-
rides (LPS) [20–22]. Of note, intermittent hypoxia induces a
redox-dependent stabilization of HIF-1 in rat pheochromocytoma
PC12 cells, which is dependent on NADPH oxidase-driven ROS,
as well as Ca2+ and mTOR signalling. In any case, increasing
ROS generation under hypoxia may trigger a redox adaptation
response that enables cancer cells to survive, owing to increased
tolerance of exogenous stress, up-regulation of survival molecules
and increased ability for drug inactivation.
In this work we analysed the biological events, triggered by
hypoxia, involved in melanoma resistance to conventional
chemotherapy. Using HS29-4T human metastatic melanoma cells
treated with etoposide, we proved that hypoxia-driven ROS
orchestrate a biphasic redox-dependent cellular response that
leads cells to escape apoptosis induced by both etoposide and
hypoxic hostile environment. We found that mitochondrial ROS
(mtROS) and NADPH oxidase ROS (noxROS) cooperate in HIF-
1 stabilization, although with a different time course. We identified
a redox-dependent circuitry linking hypoxia-driven ROS to
VEGF secretion and to increased survival and chemoresistance.
Results
Hypoxia protects Hs29-4T cells from etoposide induced
apoptosis
In order to investigate how chemoresistance develops in
melanoma, we choose human metastatic melanoma cell line
(Hs29-4T) treated with etoposide under hypoxic conditions. Our
results indicate that the number of apoptotic cells is greatly
reduced in hypoxic etoposide stimulated cells as revealed by the
50% decrease of positivity to Annexin V end Caspase 3 staining
(Fig. 1A–B). Cells viability was demonstrated by TMRM staining.
In particular, Fig. 1C shows a consistent increase of fluorescence in
cells treated with etoposide in hypoxia if compared with normoxic
control, in keeping with a more resistant and malignant
phenotype. Moreover hypoxia induces phosphorylation of Akt
protein in cells, independently from etoposide treatment (Fig. 1D).
To confirm hypoxic induced survival we investigated if oxygen
decrease affects p53 stabilization during in etoposide treatment.
Etoposide added to HS29-4T in normoxia increases p53 protein
phosphorylation leading cells to apoptosis; on the contrary p53
phosphorylation is not affected by etoposide when cells are
exposed to hypoxia (Fig. 1D).
Hypoxic-mediated oxidative stress induces survival in
Hs29-4T cells
Firstly, to clarify the role of redox hypoxic signalling in
melanoma resistance, we measured level of ROS during hypoxia.
Cells exposed to hypoxia increase by 5-fold their level of ROS, if
compared with normoxic control. The antioxidants rotenone and
DPI, affecting mitochondrial and NADPH oxidase-driven ROS
delivery, reduce the level of intracellular ROS during hypoxia
(Fig. 1E), suggesting that both these sources of ROS (mtROS and
noxROS) are active in hypoxic stimulated Hs29-4T cells. We then
evaluated how ROS affect cells survival. The results indicate that
hypoxia markedly inhibits etoposide-induced apoptosis and both
DPI and rotenone revert the hypoxic protective effect, suggesting
that mtROS and noxROS are key mediators also for melanoma
survival during hypoxia (Fig. 2A). To validate our data, we
selectively inhibited mtROS generation by siRNA targeting Rieske
Fe-S protein (component of Ubiquinol-cytochrome-c reductase in
the mithocondria) or using the dominant negative small GTP-ase
Rac-1 (RacN17), a key upstream regulator of NADPH oxidase.
The inhibition of ROS generations by these approaches increases
the number of hypoxic apoptotic cells, either treated or not with
etoposide (respectively about 6 fold and 3,5 fold, as indicated in
Fig. 2B, C). Apocinyn, a selective inhibitor of NADPH oxidase,
reverts hypoxic induced survival in etoposide-stimulated hypoxic
cells in a dose-dependent manner (Fig. 2D). Many anticancer
drugs act, at least partially, through intracellular delivery of toxic
ROS and an increased antioxidant capacity is a frequent escape
strategy for cancer cells under anti-tumour treatment. Neverthe-
less, we observed that etoposide does not affect ROS levels,
independently from exposure to hypoxia, thereby excluding a
direct involvement of the drug in ROS generation (Fig. 2E).
HIF-1a mediates cells survival in melanoma cells Hs29-4T
As HIFs transcription factors are implicated in tumour
progression, metastasis and resistance to therapy, we investigated
whether HIF-1 is involved in hypoxic-induced survival in
melanoma. Cells were transiently transfected with siRNAs
oligonucleotides targeting HIF-1a and, afterwards, cultured under
hypoxia. First, we confirmed that silencing of HIF-1a is able to
revert the ability of 1% hypoxia to elicit activation of the
transcription factor (Fig. 3A). Second, we confirm that etoposide
treatment does not further affect HIF-1 accumulation, autono-
mously with respect to oxygen concentration (Fig. 3B). Finally, the
analysis of apoptotic cells during etoposide and hypoxia treat-
ments, revealed that HIF-1a silencing under hypoxic conditions
makes cells sensitive to therapy with etoposide, thereby reverting
the protective effect exerted by hypoxia, by increasing the number
of apoptotic cells by 1,5 fold (Fig. 3C).
Hypoxia-induced ROS affect HIF-1a stabilization
Previous results indicated clearly that both ROS and HIF-1 are
mandatory for cells survival and that ROS are key molecules for
HIF-1a stabilization. In order to understand the meaning of HIF
redox regulation in cancer resistance, we analysed the effect of
different antioxidants in HIF-1a accumulation.. Data show that
both DPI and rotenone decrease HIF-1a protein expression, with
DPI acting as a more effective inhibitor (Fig. 4A). The same results
were achieved using Rieske Fe-S protein siRNA and dominant
negative RacN17, thereby confirming a direct involvement of both
mtROS and noxROS on HIF-1a expression during hypoxia
(Fig. 4B,C). To verify if ROS affect HIF-1a transcriptional activity
we measured VEGF-A mRNA, one of the main HIF-1a target
genes and a key factor for de novo tumour angiogenesis. In hypoxic
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Figure 1. Hypoxia induces cell survival in melanoma cells. Hs29-4T cells were serum-starved for 24 h and then incubated under normoxia or
hypoxia in the absence or presence of etoposide (50 mM) for additional 24 h. Different parameter revealing cell death or cell survival were examined.
(A) Percentage of apoptotic cells was measured with Annexin V staining versus propidium iodide-positive cells; averages SD values are shown in the
bar graph. *P,0,001 versus etoposide-treated under hypoxia. (B) Cells were stained with specific antibody against caspase 3. Cells positive to caspase
3 staining were revealed by flow cytometric analysis; averages 6SD values are shown in the bar graph. *P,0,001 versus etoposide-treated under
hypoxia. (C) Living cells were stained with TMRN and mitochondrial fluorescence (excitation 543 nm, emission 590 nm) was quantified by fluorimetric
assay (FluoroSkan) and normalized on protein content; averages 6SD values are shown in the bar graph. *P,0,001 versus etoposide-treated under
hypoxia. (D) After cells lysis p-Akt and p-53 proteins accumulation were assessed with western blotting. b-Actin is shown as loading control. Image
quantification reports fold increase in protein expression. (E) Hs29-4T cells were serum-starved for 24 h, then incubated under normoxia or hypoxia
for 24 h in the absence or presence of specific inhibitors of the various form of ROS, namely DPI (5 mM) and rotenone (1 mM). Hydrogen peroxide
production was evaluated by DCDF-DA and normalized on protein content. *P,0,001 versus untreated control under hypoxia.
doi:10.1371/journal.pone.0038388.g001
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Figure 2. ROS induce survival in hypoxic melanoma cells. (A) Hs29-4T cells were serum-starved for 24 h, then incubated under normoxia or
hypoxia for 24 h in the absence or presence of specific inhibitors of the various form of ROS, namely DPI (5 mM) and rotenone (1 mM). Percentage of
apoptotic cells was measured with Annexin V staining versus propidium iodide-positive cells; *P,0,001 versus Etoposide treated control under
hypoxia. (B) Cells were transfected with siRNA targeting Rieske Fe-S protein, serum-starved for 24 h and incubated in hypoxia and normoxia for
additional 24 h. Percentage of apoptotic cells was measured by flow cytometry analysis of Annexin V versus propidium iodide-positive cells. *P,0,001
versus Etoposide treated control under hypoxia. (C) Cells were transfected with dominant negative RacN17 and after 24 h of serum starvation cells
were exposed to 24 h of normoxia and hypoxia. Percentage of apoptotic cells was measured as in B. *P,0,001 versus Etoposide treated control under
hypoxia. (D) Hs29-4T cells were serum-starved for 24 h and then incubated under normoxia or hypoxia in the absence or presence of etoposide
(50 mM) for additional 24 h. Hydrogen peroxide production was evaluated by DCDF-DA and normalized on protein content. *P,0,001 versus
Etoposide treated control under hypoxia. (E) Hs29-4T cells were serum-starved for 24 h, then incubated under normoxia or hypoxia for 24 h in the
presence of Apocynin in dose crescent stimulation, 1, 10 and 30 mM. Percentage of apoptotic cells was measured with Annexin V staining versus
propidium iodide-positive cells; *P,0,001 versus Etoposide treated control under hypoxia.
doi:10.1371/journal.pone.0038388.g002
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conditions, VEGF-A mRNA levels increase by 8-fold compared
with normoxic control, while DPI and rotenone inhibit the
hypoxic-induced increase of VEGF, thereby confirming a key role
of ROS in regulating HIF-1-mediated function (Fig. 4D).
VEGF-A mediates HIF-1a-dependent cell survival
It is well known that many tumour cell lines produce large
amounts of growth factors. Therefore we investigated whether
autocrine production of growth factors are involved in survival to
etoposide induced by hypoxia in melanoma cells. Cells were
cultured in absence of exogenous growth factors, exposing them to
either hypoxia and to neutralizing antibodies targeting growth
factors that are frequently deregulated in human cancers,
including EGF, FGF-2, IGF-I, PDGF-BB, and VEGF-A. Our
results suggest that VEGF-A is the main responsible for the pro
survival effect exerted by hypoxia, as its functional blockage with a
specific neutralizing antibody increases the number of apoptotic
cells of 40% (Fig. 5A). Bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody, commonly used in combination with
chemotherapy for clinical treatment of patients, in our experi-
mental system reverts completely the protection from cell death
induced by hypoxia (Fig. 5B). Hs29-4T cells were than cultured
under normoxic conditions in the presence or absence of VEGF-
A. As shown in Fig. 5C, VEGF-A decreases the percentage of
apoptotic cells compared to untreated control. VEGF mainly
binds two tyrosine kinase receptors on endothelial cells: VEGF
receptor-1 (Flt-1) and VEGF receptor-2 (KDR) [23]. VEGFRs are
also expressed in non-endothelial cells, including haematopoietic
stem cells and monocytes, as well as in a variety of tumour
histotypes like prostate and colon cancers [24]. Our results
indicate that addition of antibodies neutralizing both receptors,
increases cells death in hypoxia. Nevertheless, the action of VEGF-
R2 neutralizing antibody has a stronger effect (3-fold of increase)
(Fig. 5D).
VEGF autocrine loop is redox dependent
ROS act as intracellular messengers following NADPH oxidase
activation due to membrane receptors activation, by a variety of
bioactive peptides including growth factors, cytokines and
hormones. Therefore we suppose that, under hypoxia, VEGF-A
stimulates NADPH oxidase to produce a second wave of ROS,
which are able to further sustain HIF-1a stabilization. Exposure of
Figure 3. HIF-1a leads melanoma cells survival. (A) Cells were transfected with siRNA targeting HIF-1a and with a control siRNA. After 24 h of
serum starvation, cells were exposed for 24 h to normoxia or hypoxia. Percentage of apoptotic cells was measured by flow cytometry analysis of
Annexin V versus propidium iodide-positive cells. *P,0,001 versus Etoposide treated control under hypoxia. (B) Hs29-4T were transfected with siRNA
targeting HIF-1a and with a control siRNA. Cells were serum-starved for 24 h and then incubated under normoxia or hypoxia for additional 24 h. HIF-
1a expression was analysed by immunoblot. b-Actin is shown as loading control. (C) Melanoma cells were serum-starved for 24 h and then were
treated in the absence or presence of etoposide (50 mM) and incubated under normoxia or hypoxia for additional 24 h. HIF-1a expression was
analysed by immunoblot. b-Actin is shown as loading control.
doi:10.1371/journal.pone.0038388.g003
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melanoma cells to VEGF at 5, 10, 15, and 30 min leads to a
significant rise of intracellular ROS both in normoxia and hypoxia
peaking at 15 minutes after stimulation. This effect is strongly
amplified under hypoxic conditions (Fig. 6A). To validate if
autocrine VEGF-A affects HIF-1a protein stabilization during
hypoxia, Hs29-4T cells were treated with the neutralizing
antibody for VEGF-A (Fig. 6B), or with Bevacizumab under
normoxic and hypoxic conditions for 4 and 24 h (Fig. 6C). Both
VEGF-A neutralizing antibody and Bevacizumab, abrogate
hypoxic induction of HIF-1a only at 24 h. To identify the specific
receptor used by autocrine VEGF-A in hypoxia, Hs29-4T cells
were treated with VEGF-R1 and VEGF-R2 neutralizing antibod-
ies for 24 h. The results indicate that VEGF-R2 neutralizing
antibody inhibits HIF-1a protein accumulation, suggesting VEGF-
R2 as the key mediator of hypoxia-induced survival (Fig. 6D). To
analyse the differential time course of early and late ROS during
hypoxia exposure of melanoma, we treated we treated Hs29-4T
with Bevacizumab for 4 and 24 h. The obtained data show that
Bevacizumab is able to inhibit ROS delivery under hypoxic
conditions, in a dose dependent fashion, only after 24 h (Fig. 7A,
B). Moreover we observed that early inhibition of NADPH oxidase
by DPI does not affect HIF-1a, whereas rotenone efficiently blocks
HIF-1a accumulation (Fig. 7C, D). These observation is further
confirmed by stimulation of Hs29-4T cells with Apocynin, used
again at 4 and 24 hrs. In keeping, this selective NADPH inhibitor
is more efficient in inhibiting HIF-1a protein accumulation at
24 hrs, than earlier.
Therefore, it is likely that hypoxia engages two different ROS
sources, being mitochondria the earliest one and NADPH oxidase
the latest. We propose that mitochondrial ROS delivery behaves
as the start button, when hypoxic exposure begins, but later on,
VEGF-A secreted owing to the early HIF-1 signalling, through its
receptor VEGF-R2, elicits a NADPH oxidase-driven second wave
of ROS, able to further sustain HIF-1a expression leading to cells
survival (Fig. 8).
Discussion
Metastatic melanoma is a very aggressive tumour, unfortunately
very resistant to chemotherapy. Etoposide and cisplatin-based
combination therapy has only partial effects for patients survival,
limiting to 10% the effective responsiveness [25]. The exact
mechanisms exploited by aggressive melanoma to achieve this
high intrinsic drug resistance is currently unknown and is at
present a real challenge for molecular oncologists. Indeed, up to
now immunotherapy using interleukin-2 and interferon-c is the
most used pharmacological approach for this kind of neoplasia
[26]. Herein we report that etoposide resistance in human
aggressive melanoma Hs29-4T cells is tightly correlated to a two
waved redox-based VEGF autocrine loop, exploiting hypoxic
environment. Our data indicate that: i) 1% O2 hypoxia protects
cells from etoposide-induced cell death through an early ROS
delivery by mitochondria; ii) this leads to a redox stabilization of
HIF-1 leading to autocrine secretion of VEGF-A; iii) VEGF-A acts
as a survival factor for melanoma cells through interaction with its
Figure 4. ROS stabilize HIF-1a protein under hypoxia. (A) Hs29-4T cells serum-starved for 24 h and incubated under normoxia or hypoxia for
additional 24 h, in the presence or absence of DPI (5 mM) and rotenone (1 mM). HIF1-a expression was analysed with immunoblot. b-Actin is shown as
loading control. (B) Cells were transfected with siRNA targeting Rieske Fe-S protein and after 24 h of serum starvation were incubated under
normoxia and hypoxia for 24 h. HIF-1a expression was evaluated by immunoblot. b-Actin is shown as loading control. (C) Cells were trasfected with
dominant negative RacN17, serum-starved for 24 h and incubated under hypoxic and normoxic conditions for additional 24 h. HIF-1a expression was
analysed by immunoblot. b-Actin is shown as loading control. (D) Hs29-4T cells were serum-starved for 24 h and incubated under normoxia or
hypoxia in the absence or presence of DPI (5 mM) and rotenone (1 mM). mRNA for VEGF was measured by real time PCR. *P,0,001 versus untreated
control under hypoxia.
doi:10.1371/journal.pone.0038388.g004
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receptor VEGFR2, leading to generation of a second wave of
ROS through NADPH oxidase, which ultimately causes a long
lasting HIF-1 stabilization, enhancing melanoma cell survival to
etoposide chemotherapy.
Etoposide is known, as many other chemotherapic agents, to
cause apoptosis by increasing ROS, leading cells to overwhelming
toxic threshold. Of note, in our experimental model etoposide did
not increase ROS to toxic concentration, even in normoxia, likely
due to the high intrinsic antioxidant/scavenger ability of
melanoma cells [27,28]. In keeping with this, melanoma cells
are highly sensitive to changes in the intracellular redox balance
and actively respond exploiting these extra ROS by engaging
motility [17] and, as demonstrated herein, chemoresistance. We
also excluded a direct effect of etoposide, as a known topoisom-
erase II inhibitor, on HIF-1 protein stabilization. Our data
indicate HIF-1 as the driver of hypoxic-dependent pathway
mediating melanoma survival and in particular we emphasize the
role of its redox-based stabilization due to ROS delivery during
hypoxia. This conclusion was supported by experiments per-
formed using siRNA targeting HIF-1a, which completely blocked
hypoxia-induced resistance to etoposide. HIF-1 has already been
proposed as a key player of cancer cells survival, and mechanisms
proposed are mainly correlated to its ability to prompt anaerobic
glycolitic metabolism, or expression of anti-apoptotic proteins, as
Bcl-2, Bcl-XL or down regulation of pro-apoptotic proteins such as
Bid or Bax [29,30]. In melanoma cells HIF-1 drives a survival
response mainly mediated by the autocrine production of VEGF-
A, acting on melanoma cells themselves and eliciting canonical
Akt-dependent pro-survival signals.
Intratumoural hypoxia can produce several different effects on
cancer cells, ranging from metabolic reprogramming towards a
glycolitic phenotype, over-expression of ABC transporters, selec-
tion of mutated cells whose apoptotic process is deficient, or
protection from apoptotic inducers. Indeed, hypoxic cancer cells
Figure 5. VEGF induces survival in hypoxic melanoma cells. HS29-4T cells serum-starved in for 24 h, then incubated under normoxia or
hypoxia in the absence or presence of etoposide and treated with following conditions: (A) neutralizing antibody for 4 different growth factor, anti-
EGF (50 ng/mL), anti-FGF-2 (1 mg/mL), anti-IGF-I (10 mg/mL), anti-PDGF-BB (100 ng/mL), and anti-VEGF (50 ng/mL) *P,0,001 versus untreated control
under hypoxia. (B) VEGF (30 ng/ml); (C) bevacizumab 250 ng/ml; (D) neutralizing antibody for VEGF receptors KDR and Flt-1. Percentage of apoptotic
cells was measured by Annexin V staining. *P,0,001 versus untreated control under hypoxia.
doi:10.1371/journal.pone.0038388.g005
Redox Regulation of Melanoma Malignancy
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e38388
are more invasive, resistant to apoptosis and ultimately to
chemotherapy and radiation [31] therapy [8,32]. Moreover
mounting evidence indicate that hypoxic cancer cells undergo
exposure to oxidative stress, thereby developing adaptive strategies
to survive to the hostile milieu [33]. Of note hypoxic cells can
enhance their antioxidant capacity and hypoxia can behave as a
promoting factor for this behaviour, with a possible correlation
with resistance to therapy [5,34]. We also recently reported that
aggressive melanoma cells respond to hypoxia engaging a motogen
escaping strategy, based on redox stabilization of HIF-1 and
activation of the Met protoncogene, allowing a proteolytic motility
enhancing metastatic dissemination to lungs [17].
Our data contribute to the long-lasting debate about the role of
ROS in oxygen sensing and activation of HIF-1a [12,28,35,36].
Under normoxia, a variety of stimuli including growth factors,
hormones, vasoactive peptides, metal ions, hydrogen peroxide,
and certain nitric oxide donors, are known to stabilize HIF-1a,
using at least in part redox-based mechanisms. During mild
hypoxia (1–3% O2), at least two mechanisms have been proposed
to explain the paradoxical production of ROS during oxygen lack.
First, mitochondrial ROS have been involved, through deregula-
tion of complex III of electron transfer chain at the level of Fe-S
Rieske protein. Second, while mitochondrial ROS appear a main
font during hypoxia, some recent studies also support the
activation of Rac-1/NADPH oxidase complex through Akt or
Src-mediated pathways [20,37]. Whatever the mechanism to
produce ROS, increased generation of OH? from H2O2 through a
Fenton reaction, is acknowledged to promote the conversion of
Fe2+ to Fe3+, leading to PHD inactivation. This ROS-mediated
inhibition of PHDs, enzymes devoted to oxygen-dependent
degradation of HIF-1, has been involved in the redox-dependent
stabilization of HIF-1. Another proposed mechanism of oxidative
stabilization of HIF-1a is that ROS activate multiple signalling
pathways, such as Akt and p38MAPK, which may render PHD
catalytically inactive [20,38].Of note, attenuation of ROS levels by
antioxidants (such as N-acetyl cysteine, ascorbate, and catalase, or
genetic down-modulation of NADPH oxidase-4, were found to
decrease HIF-1a expression [21,39]. In keeping with the key role
exerted by ROS in sensing the effects of hypoxia, Gao et al
reported that the anti-tumourigenic effect of antioxidants as N-
acetyl cysteine and vitamin C in murine models of Myc-mediated
tumourigenesis are indeed HIF-1-dependent [15]. We herein
confirm for hypoxic ROS a key role for HIF-1 stabilization and
activation of its transcriptional response, but we identify two
distinct waves of ROS delivery. The first one is mediated by
mitochondria, as indicated by rotenone treatment, which
decreases the electron flux from complex I and hence inhibits
ROS delivery from the downstream complex III, or by silencing
the Rieske protein, which is the direct responsible for ROS
delivery. The second wave is driven by NADPH oxidase activation
in response to VEGF-A interaction with its VEGF-R2. Of note the
first wave of mitochondrial ROS plays a mandatory role in
Figure 6. VEGF derived ROS stabilize HIF-1a protein. (A) Hs29-4T cells were serum-starved for 24 h and then incubated under normoxia or
hypoxia in presence of recombinant VEGF 30 ng/ml from 0 to 30 min. Hydrogen peroxide production was evaluated with DCDF-DA and normalized
on protein content. Cells were serum-starved for 24 h and incubated under normoxia or hypoxia for 24 h in the following different conditions: (B)
neutralizing antibody for VEGF; (C) increasing concentrations of bevacizumab; (D) neutralizing antibody for KDR and Flt-1 receptors. HIF-1a
expression was revealed by immunoblot. b-Actin is shown as loading control. *P,0,001 in A versus untreated control under hypoxia at 15 min.
doi:10.1371/journal.pone.0038388.g006
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eliciting the autocrine production of VEGF-A from melanoma
cells, as revealed by the effect of its block on downstream events as
VEGF-A expression or VEGF-R2 activation. This second wave of
NADPH-driven ROS concurs to a further redox-based stabiliza-
tion of HIF-1. Although the involvement of early and late ROS in
cancer cells survival to chemotherapeutic agents is a novel finding,
VEGF-A has already been involved in an autocrine survival loop
in hypoxic colon cancer cells [40]. In keeping with the key role
exerted by VEGF-A for chemoresistance, bevacizumab, a
humanized anti-VEGF monoclonal antibody increases the efficacy
of chemotherapy for the treatment of metastatic colorectal cancer
[41,42]. Here we report that bevacizumab is also active in
aggressive melanoma cells, as it completely reverts the hypoxic
induced survival, increasing sensitivity to etoposide. In keeping
with our model (Fig. 8), bevacizumab is active in inhibiting the
late, VEGF-dependent, HIF-1 activation. On the basis of these
results we propose that in aggressive melanoma, the presence of a
functional VEGF-A/VEGF-R2 autocrine loop, should render cells
more resistant to chemotherapy-induced apoptosis under hypoxic
stressing condition, which may contribute to treatment failure.
Expression of VEGF-R(s) has been correlated with stem-like traits
and CD133 expression, and hypoxia is acknowledged to be a
favourable environmental condition for the maintenance of the
stem cell phenotype [43,44]. We can therefore speculate that in
Figure 7. Bevacizumab inhibits ROS production under hypoxia. (A, B) Hs29-4T cells were serum-starved for 24 h. Cells were then incubated
under normoxia or hypoxia of increasing concentrations of bevacizumab (Bev) for 4 and 24 h. Hydrogen peroxide production was evaluated with
DCDF-DA and normalized on protein content. *P,0,001 versus untreated control under hypoxia. (C, D) HIF-1a expression was assessed by Western
blotting in Hs29-4T cells serum-starved for 4 and 24 h and incubated under normoxia or hypoxia in the absence or presence of DPI (5 mM) and
rotenone (1 mM) for additional 24 h. (E) HIF-1a expression was assessed by Western blotting in Hs29-4T cells serum-starved for 24 h and incubated
under normoxia or hypoxia in the presence of Apocynin (30 mM) for additional 4 and 24 h.
doi:10.1371/journal.pone.0038388.g007
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melanoma hypoxia could select VEGF-A sensitive/VEGF-R2
positive populations, in which the two waves of ROS synergize to
grant survival and resistance to chemotherapy. In keeping with
this idea, recently it has been reported that in skin cancers blocking
VEGFR2 caused tumour regression by impairing cancer stem cells
renewal properties, suggesting that, besides its well-known effect
on angiogenesis, VEGF affects tumour growth by promoting
cancer stem cells expansion [45]. Therefore, beside its acknowl-
edged role for hematopoietic malignancies, VEGF-R2 should be
proposed as a stem-like marker also in solid tumors. Future study
should explore the possibility that VEGFR2-positive cells repre-
sent the more malignant, therapy resistant, tumor cells. Hence, our
data propose the couple HIF-1/VEGF-A as mandatory players in
melanoma resistance to therapy, acting as a reciprocal redox based
circuitry. Future studies combining anti-VEGF and antioxidant
therapies should therefore have important implications for
treatment of malignant melanoma.
Materials and Methods
Materials
Unless specified all reagents were obtained from Sigma. Hs29-
4T cells were from ATCC, all antibodies were from Santa Cruz
Biotechnology, except the anti-HIF-1a which was from BD. DCF-
DA was from Molecular Probes. PVDF was from Millipore.
siRNA oligonucleotides targeting HIF-1a (target sequence: 59-
AAAGGACAAGUCACCACAGGA-39) and siRNA targeting the
Rieske iron-sulfur protein (target sequence 59-AAUGCCGU-
CACCCAGUUCGUU-39) were obtained from Qiagen. An-
nexin-V fluorescein isothiocyanate apoptosis kit was from Roche
Diagnostic. Caspase Assay kit was from Immunoistochemistry
technologies.
Cell culture and transfections
Hs29-4T cells were cultured in DMEM supplemented with 10%
FCS, in 10% CO2 humidified atmosphere. Experiments under
hypoxic condition (1% O2) were performed in the hypoxic
incubator. For transient transfections, Hs29-4T cells were plated
in 60-mm cell culture dishes and grown to 80% confluence. The
siRNA was diluted to a final concentration of 20 nM. Transfec-
tions were performed using Lipofectamine (Invitrogen), following
manufacturer’s recommendations 48 h before treatment with the
indicated conditions.
Flow cytometry and apoptotic cells analysis
Annexin-V staining was performed using the Annexin-V
fluorescein isothiocyanate apoptosis kit according to the manu-
facturer’s instructions. Gated cells were plotted on a dot-plot
showing Annexin-V staining and propidium iodide (PI) staining.
Index of apoptotic cells was determinate summing Annexin V
positive (early apoptotic) cells and Annexin/PI positive (late
apoptotic).
Western blot analysis
Hs29-4T (16106) cells derived from our experimental condi-
tions were lysed for 20 min on ice in 500 ml of complete RIPA lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-
40, 2 mM EGTA, 1 mM sodium orthovanadate, 1 mM phenyl-
methanesulphonyl-fluoride, 10 mg/ml aprotinin, 10 mg/ml leu-
peptin). Lysates were separated by SDS/PAGE, and transferred
onto nitrocellulose. Immunoblots were incubated in 3% BSA,
10 mM Tris/HCl (pH 7.5), 1 mM EDTA, and 0.1% Tween 20,
for 1 h at room temperature, probed first with specific antibodies
and then with secondary antibodies.
Tetramethylrhodamine-methyl ester (TMRM) staining
and imaging
For mitochondria visualization in living cells, Hs29-4T cells
treated as previously described were stained for 15 min at 37uC
with 1 mM TMRM. Loading of TMRM in metabolically active
mitochondria is driven by mitochondrial membrane potential that
is well maintained by healthy living cells. The disruption of this
membrane potential causes an abrupt decrease in mitochondrial
fluorescence that is a distinctive feature of programmed cell death.
This potentiometric dye (excitation 543 nm, emission 590 nm) was
quantified by fluorimetric assay (FluoroSkan).
Assay of intracellular ROS
To evaluate the intracellular production of H2O2, DCF-DA was
added (final concentration, 5 mM) 3 min before the end of the
incubation time. Cells were lysed in 1 ml of RIPA buffer and
analysed immediately by fluorescence analysis using a Perkin
Elmer Fluorescence Spectrophotometer 650-10S equipped with a
Xenon Power Supply (excitation 488 nm, emission 510 nm).
Statistical analysis
Data are presented as means 6 SD from at least three
independent experiments. Statistical analysis of the data was
performed using the Student t test. P values of #0.001were
considered statistically significant.
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Figure 8. Schematic illustration of VEGF autocrine loop in HS-
294T. Early induction of HIF-1a mediated by mitochondrial ROS and
late induction of HIF-1a mediated by NADPH oxidase.
doi:10.1371/journal.pone.0038388.g008
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